TY - JOUR
T1 - Cochlear Implant Performance in Children Deafened by Torch Infection
T2 - 15th Asian Congress on Biotechnology in conjunction with the 7th International Symposium on Biomedical Engineering, ACB-ISBE 2022
AU - Sinaga, Gideon Hot Partogi
AU - Susanto, Johannes Elia
AU - Harlena, Filza Amara Kamila
AU - Oktavianti, Sakina
AU - Putri, Rizki Amalia
AU - Yusuf, Prasandhya Astagiri
AU - Priyono, Harim
N1 - Publisher Copyright:
© 2024 American Institute of Physics Inc.. All rights reserved.
PY - 2024/3/7
Y1 - 2024/3/7
N2 - TORCH infection is described as perinatal infections caused by toxoplasma (To), rubella (R), cytomegalovirus (C), and herpes simplex virus (HSV). Sensorineural hearing loss (SNHL) is the most prevalent postnatal symptom of TORCH infection and may progress to severe and profound SNHL, in which cochlear implant (CI) may be considered. This scoping review will map data on cochlear implantation performance in TORCH-deafened children. Twenty-six articles were reviewed. Most of the studies included (61.5%, n=16) were CMV studies, implying that CMV infection was still the primary etiology for sensorineural hearing loss associated with TORCH infection syndrome. CI is a viable option in the treatment of congenital cytomegalovirus (cCMV), leading to improvements in hearing and language. However, when compared to Cx26 mutation as control, poorer performance was reported for cCMV. CI is also recommended for congenital rubella due to increased speech production, which results in a higher quality of life and the ability to attend regular school. CI was associated with several positive outcomes in toxoplasmosis, including age-appropriate speech perception and social-emotional development. These positive outcomes, however, are only possible with adequate environmental and parental support. No research regarding CI outcomes on patients of hearing loss for specific HSV infection. Nevertheless, CI was recommended for its rehabilitative outcomes. Being one of the first reviews in this context, CI is recommended especially if it is done as early as possible. Nevertheless, prevention measures such as TORCH infection screening and ABR testing are required, particularly in low-and-middle-income countries.
AB - TORCH infection is described as perinatal infections caused by toxoplasma (To), rubella (R), cytomegalovirus (C), and herpes simplex virus (HSV). Sensorineural hearing loss (SNHL) is the most prevalent postnatal symptom of TORCH infection and may progress to severe and profound SNHL, in which cochlear implant (CI) may be considered. This scoping review will map data on cochlear implantation performance in TORCH-deafened children. Twenty-six articles were reviewed. Most of the studies included (61.5%, n=16) were CMV studies, implying that CMV infection was still the primary etiology for sensorineural hearing loss associated with TORCH infection syndrome. CI is a viable option in the treatment of congenital cytomegalovirus (cCMV), leading to improvements in hearing and language. However, when compared to Cx26 mutation as control, poorer performance was reported for cCMV. CI is also recommended for congenital rubella due to increased speech production, which results in a higher quality of life and the ability to attend regular school. CI was associated with several positive outcomes in toxoplasmosis, including age-appropriate speech perception and social-emotional development. These positive outcomes, however, are only possible with adequate environmental and parental support. No research regarding CI outcomes on patients of hearing loss for specific HSV infection. Nevertheless, CI was recommended for its rehabilitative outcomes. Being one of the first reviews in this context, CI is recommended especially if it is done as early as possible. Nevertheless, prevention measures such as TORCH infection screening and ABR testing are required, particularly in low-and-middle-income countries.
KW - auditory performance
KW - cochlear implant
KW - congenital sensorineural hearing loss
KW - TORCH infection
UR - http://www.scopus.com/inward/record.url?scp=85188440578&partnerID=8YFLogxK
U2 - 10.1063/5.0203457
DO - 10.1063/5.0203457
M3 - Conference article
AN - SCOPUS:85188440578
SN - 0094-243X
VL - 3080
JO - AIP Conference Proceedings
JF - AIP Conference Proceedings
IS - 1
M1 - 110001
Y2 - 2 October 2022 through 6 October 2022
ER -